NDAINJECTIONINJECTABLE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
CARDIOGEN-82 (rubidium chloride rb-82) by Bracco is 82 is analogous to potassium ion (k) in its biochemical behavior and is extracted by the myocardium in proportion to the blood flow. First approved in 1989.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIOGEN-82 is a rubidium chloride RB-82 injectable radiotracer used for myocardial perfusion imaging in nuclear cardiology. It functions as a potassium analog that accumulates in viable myocardium proportional to blood flow, enabling detection of ischemia and infarction. The tracer is retained in healthy tissue while clearing from necrotic areas, providing real-time assessment of cardiac viability.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating defensive positioning and potential team consolidation or transition planning.
Mechanism of Action
82 is analogous to potassium ion (K) in its biochemical behavior and is extracted by the myocardium in proportion to the blood flow. Rb participates in the sodium-potassium (Na/K) ion exchange pumps that are present in cell membranes. The intracellular uptake of Rb 82 requires maintenance of ionic…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning
Started Sep 2011
155 enrolled
Radiation Exposure
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites
Started Sep 2011
72 enrolled
Radiation Exposure
Career Relevance
Working on CARDIOGEN-82 positions you in specialized nuclear/molecular imaging—a niche but stable segment within cardiology diagnostics. With only 4 linked roles, this represents a highly specialized career path focused on account management and clinical support rather than broad commercial scale.
Worked on CARDIOGEN-82 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.